← Schmidt Sciences AI2050 Fellowship MODERATE Neuropharm/CCT
Programme Research
Schmidt Sciences AI2050 Fellowship ·
Programme Site
MEDIUM confidence Researched 2026-08-04 20:50 · profile: researcher
The AI2050 Fellowship funds early-career and senior researchers worldwide to pursue ambitious, high-risk projects that harness AI to create immense societal benefits by 2050, focusing on hard problems such as building AI scientists, ensuring AI safety and trustworthiness, and advancing AI for biological and medical research. It exists to turn AI's potential into tangible benefits for humanity, fostering a collaborative community and providing substantial financial and computational support.
Eligibility: Open to early-career and senior researchers globally; early-career fellows are typically postdocs or faculty within a few years of PhD; senior fellows are established professors. No explicit citizenship restrictions, but global and LMIC inclusion is valued. Evaluation criteria (inferred from program mission and past cohorts): 1) Alignment with AI2050's 'hard problems' (e.g., AI for scientific discovery, trustworthy AI, AI for health and societal resilience). 2) Ambition and potential impact of the proposed research to benefit humanity by 2050. 3) Technical novelty and feasibility of the approach. 4) Track record of the applicant (publications, collaborations, recognition). 5) Collaborative potential and fit with the AI2050 community. 6) For early-career, evidence of independence and promise. 7) Computational needs may be considered for additional funding.
Past cohorts include 99 fellows across 8 countries and 42 institutions, with profiles ranging from AI safety (LLM trustworthiness, self-driving car safety) to AI for science (drug discovery, generative chemistry) and AI for social good (cross-cultural values datasets, Humanity's Last Exam benchmark). Named 2025 senior fellows include professors from Toronto, Stanford, NYU, Berkeley, Oxford, and Washington, working on AI chemists, mechanistic interpretability, scientific AGI, theory of mind, code verification, historical reasoning, and decentralized LLMs. Early-career fellows include David Ifeoluwa Adelani (Mila) and Michael Albergo (NYU), indicating a mix of top-tier academic institutions and diverse backgrounds.
The ideal applicant is an early-career researcher with a strong publication record and a bold, well-defined project that directly addresses one of AI2050's hard problems, particularly in AI for health or scientific discovery. They demonstrate technical excellence, interdisciplinary thinking, and a clear vision for how their work will benefit humanity at scale, with potential for collaboration within the AI2050 community.
For Eniola, the strongest angle is to center the application on the CCT model and its extension via TOPOLOGIX, framing it as an AI-driven approach to solving the hard problem of AI for biological and medical research—specifically, using machine learning and dynamical systems to prevent addiction and predict drug resistance, which are critical global health challenges. This directly matches AI2050's mission to support AI for health and societal resilience, and leverages Eniola's unique multi-domain expertise (pharmacology, ML, TDA) and LMIC perspective, which the program values. The CCT model's pre-registered hypotheses and Bayesian calibration demonstrate scientific rigor, while TOPOLOGIX's superior performance over structure-based baselines shows practical impact.
Eligibility: The AI2050 Early Career Fellowship typically requires a PhD or equivalent; Eniola has a B.Pharm and is enrolled in an M.Sc., which may make her ineligible for the early-career track. The program is highly competitive, with only 21 early-career fellows selected globally, and past winners are predominantly from top-tier universities; Eniola's independent researcher status and lack of a PhD may be a disadvantage. Additionally, the program's focus on 'hard problems' may require a more established track record than Eniola currently has, though her preprints and collaborations with renowned researchers (Berridge, Gershman, Daw) help.
2026-08-04 20:17 · medium confidence
2026-08-01 17:31 · medium confidence